Vijaya Diagnostic Q1 FY27: Income ₹239.5 Cr, PAT ₹53.1 Cr

Key takeaway from the June 2026 quarter update

Vijaya Diagnostic Centre Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported total income of ₹239.5122 crore on a consolidated basis for the quarter. Consolidated profit after tax (PAT) for the period was ₹53.1011 crore. On the standalone side, total income was reported at ₹227.5572 crore, while standalone PAT was ₹53.1476 crore. The company also said its Board of Directors proposed a dividend of ₹2 per equity share for FY2025-26, subject to member approval. The update matters because it combines quarterly performance disclosure with a dividend recommendation, both of which can influence investor expectations.

What the company released and when

The company said it released unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. A board meeting was scheduled for August 6, 2026, to consider these unaudited results. The results date mentioned in the data was August 06, 2026. Separately, an earnings conference call was scheduled for August 7, 2026 at 10:30 AM IST. The call was slated to be hosted with MD and CEO Suprita Reddy and CFO Narasimha Raju. These events create a clear timeline around the disclosures and the opportunity for management commentary.

Standalone performance: total income and profit

For the quarter ended June 30, 2026, Vijaya Diagnostic Centre reported standalone total income of ₹227.5572 crore. Standalone profit after tax for the same period stood at ₹53.1476 crore. The company’s disclosures distinguish standalone from consolidated, which is useful for readers tracking performance of the core entity versus the group. The PAT number is presented in the provided text as the same ₹5,314.76 lakhs figure across references for the quarter. While the article does not provide a full standalone profit and loss line-up for June 2026, it clearly states the income and PAT figures. Investors typically compare these against prior quarters and years, but the text limits explicit standalone comparisons.

Consolidated performance: group income and PAT

On a consolidated basis, total income for the quarter ended June 30, 2026 was ₹239.5122 crore. Consolidated PAT for the group during this period was ₹53.1011 crore. The company also stated earlier that it reported total income of ₹23,951.22 lakhs and profit after tax of ₹5,314.76 lakhs for the period, which aligns with the consolidated income and a standalone PAT reference in the text. The consolidated income being higher than standalone suggests contributions from subsidiaries or consolidation adjustments, although the article does not detail the components. The difference between standalone and consolidated PAT is small in the figures presented.

Dividend proposal: ₹2 per share for FY2025-26

The Board of Directors proposed and recommended a dividend of ₹2 per equity share of Re 1 each, stated as 200%, for the financial year 2025-26. The dividend is subject to member approval. The disclosure does not specify a record date or payment timeline in the provided text. It also does not mention the dividend amount in aggregate or the payout ratio for FY2025-26. Still, the per-share dividend recommendation is a direct, actionable datapoint for shareholders awaiting the AGM process.

Quarterly snapshot: revenue, profit and key line items (June 2025 table)

The article includes a quarterly table labelled with fiscal periods such as Jun 25 and Mar 26, with figures in ₹ crore except per share values, and a note that comparison is on a QoQ basis. For Jun 25, Total Revenue was ₹188.05 crore, Net Income was ₹38.34 crore, and Net Income Before Taxes was ₹52.21 crore. Operating Income was ₹52.64 crore, while Total Operating Expense was ₹135.41 crore. Depreciation and amortization was ₹20.89 crore in Jun 25. Diluted Normalized EPS was 3.75 for Jun 25.

The same section of the text also states Jun 25 revenue of ₹188.05 crore represented QoQ growth of 8.55% from ₹173.24 crore and YoY growth of 20.38%. It also cites Net Profit of ₹38.34 crore, and Profit Before Tax of ₹52.21 crore with QoQ and YoY changes. These comparisons are explicitly presented for the Jun 25 period in the provided content.

Operational metrics highlighted in the data

The article also contains operational datapoints for test volumes and footfall. It states that total tests conducted in Q4FY26 reached 4.49 million, up 18.5% YoY, and total tests for FY26 were 16.92 million. Footfall for Q4FY26 was stated at 1.21 million, up 15.8% YoY, while FY26 footfall was 4.68 million. Average realization per footfall in Q4FY26 was ₹1,808, up 9.3% YoY, and average realization per test for the quarter was ₹488. In another section, the company is described as having performed 3.94 million tests in a quarter with 1.10 million footfalls, and an average realization per test of ₹477, alongside a wellness share of 14.2%.

Valuation and market dashboard numbers cited

The text provides several market snapshot indicators. It lists market capitalisation of ₹13,847.01 crore and CMP of ₹1,344.4. It also reports a P/E ratio (TTM) of 80.77x and EPS (TTM) of 14.01. Quarterly earnings growth YoY is shown as 37.49. These are presented as point-in-time metrics and do not include the date of capture beyond the broader results context. Readers typically use such metrics to compare valuation across diagnostic and healthcare service peers, but the article itself does not provide peer comparisons.

What investors may watch next

The scheduled earnings call on August 7, 2026 with the MD and CEO and the CFO is the next defined event in the timeline. Investors will also watch for details linked to the proposed dividend, including member approval and any subsequent dates. The gap between standalone and consolidated income is visible in the disclosed figures, and management commentary may clarify the drivers. Operational metrics such as test volumes, footfall, and realizations are also likely to remain in focus given their presence in the broader performance discussion within the provided data. For now, the clearest confirmed datapoints are the June 2026 quarter income and PAT numbers and the ₹2 per share dividend recommendation.

Conclusion

Vijaya Diagnostic Centre’s June 30, 2026 quarter update reported consolidated total income of ₹239.5122 crore and consolidated PAT of ₹53.1011 crore, with standalone total income of ₹227.5572 crore and standalone PAT of ₹53.1476 crore. The board’s proposed ₹2 per share dividend for FY2025-26 adds a shareholder-return element to the announcement. The next milestones are the board meeting dated August 6, 2026 for considering unaudited results and the earnings call on August 7, 2026 at 10:30 AM IST, where management is expected to discuss the quarter.